Cencora, Inc.
Key Metrics
- Previous Close
- $317.10
- 52-Week Range
- $244.82 – $377.54
- Market Cap
- $60.05B
- P/E (TTM)
- 23.34
- EPS (TTM)
- 13.48
- Dividend Yield
- 0.76%
Advanced Metrics
- Price/Book
- 19.68
- PEG Ratio
- 0.66
- Return on Equity
- 96.87%
- Return on Assets
- 3.56%
- Gross Margin
- 3.96%
- Operating Margin
- 1.41%
- Profit Margin
- 0.79%
- Current Ratio
- 0.94
- Debt/Equity
- 4.47
- Total Debt
- $14.46B
- Free Cash Flow
- $2.04B
- Revenue Growth
- 5.10%
- Earnings Growth
- 11.90%
- Enterprise Value
- $72.35B
Market Snapshot
About
Cencora, Inc., formerly AmerisourceBergen, is a global pharmaceutical solutions organization providing drug distribution, specialty pharmacy services, and solutions to manufacturers, pharmacies, hospitals, and other healthcare providers. The company distributes branded and generic pharmaceuticals, over-the-counter products, and healthcare supplies to retail pharmacies, health systems, physician practices, and other customers across the United States and internationally. Cencora operates specialty pharmacy and patient support services for complex therapies including oncology, rare diseases, and biologics. The company also provides commercialization services, data analytics, and consulting to pharmaceutical manufacturers. Founded in 2001 through the merger of AmeriSource and Bergen Brunswig and headquartered in Conshohocken, Pennsylvania, Cencora is one of the largest pharmaceutical distributors globally. The company benefits from essential role in pharmaceutical supply chains, scale advantages, specialty pharmacy growth, and manufacturer services revenues. Cencora faces opioid litigation and settlements, generic drug pricing pressures, customer concentration, and competitive markets. The company continues to focus on specialty pharmaceuticals, global expansion, manufacturer solutions, and operational efficiency.